LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

Home・Lista de Ações・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Abrir

SetorSaúde

72.78 13.61

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

63.92

Máximo

73.23

Indicadores-chave
By Trading Economics
Rendimento	-317M -142M
Vendas	98M 452M
P/E Médio do Setor	25.027 49.8
Margem de lucro	-31.342
Funcionários	423
EBITDA	-3.5M 281M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+40.99% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1.7B 7.6B
Abertura anterior	59.17
Fecho anterior	72.78

Sentimento de Notícias

By Acuity

50%

175 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

60.49 / 70.14 Suporte e Resistência

Halozyme Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de mai. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 de mai. de 2026, 23:46 UTC

Conversa de Mercado

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 de mai. de 2026, 23:33 UTC

Conversa de Mercado

Gold Rises on Possible Position Adjustments -- Market Talk

11 de mai. de 2026, 22:37 UTC

Conversa de Mercado

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 de mai. de 2026, 22:32 UTC

Ganhos

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 de mai. de 2026, 22:02 UTC

Conversa de Mercado

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 de mai. de 2026, 21:49 UTC

Ganhos

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 de mai. de 2026, 21:42 UTC

Conversa de Mercado

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 de mai. de 2026, 21:31 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 de mai. de 2026, 21:23 UTC

Aquisições, Fusões, Aquisições de Empresas

CSG Systems Sale to NEC Gets CFIUS Clearance

11 de mai. de 2026, 21:12 UTC

Ganhos

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 de mai. de 2026, 21:12 UTC

Ganhos

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

11 de mai. de 2026, 20:44 UTC

Ganhos

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 de mai. de 2026, 20:43 UTC

Ganhos

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 de mai. de 2026, 20:32 UTC

Ganhos

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 de mai. de 2026, 20:32 UTC

Ganhos

CleanSpark 2Q Rev $136.4M >CLSK

11 de mai. de 2026, 20:30 UTC

Ganhos

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Cont Ops EPS $2.24 >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Rev $1.6B >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Adj EPS $2.83 >STE

11 de mai. de 2026, 20:22 UTC

Ações em Alta

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 de mai. de 2026, 19:37 UTC

Ganhos

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 de mai. de 2026, 19:32 UTC

Conversa de Mercado

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparação entre Pares

Variação de preço

Halozyme Therapeutics Inc Previsão

Preço-alvo

By TipRanks

40.99% parte superior

Previsão para 12 meses

Média 90.4 USD 40.99%

Máximo 96 USD

Mínimo 75 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

60.49 / 70.14Suporte e Resistência

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimento

By Acuity

175 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.